Taylor & Francis Group
Browse
usbr_a_1575276_sm2204.pdf (220.59 kB)

Univariate Versus Multivariate Surrogates in the Single-Trial Setting

Download (220.59 kB)
Version 2 2019-05-13, 15:36
Version 1 2019-03-15, 15:35
journal contribution
posted on 2019-05-13, 15:36 authored by Wim Van der Elst, Ariel Abad Alonso, Helena Geys, Paul Meyvisch, Luc Bijnens, Rudradev Sengupta, Geert Molenberghs

Abstract–In spite of medical and methodological advances, the identification of good surrogate endpoints has remained a challenging endeavor. This may, at least partially, be attributable to the fact that most researchers have only focused on univariate surrogates endpoints. In the present work, we argue in favor of using multivariate surrogates and introduce two new complementary metrics to assess their validity. The first one, the so-called individual causal association, quantifies the association between the individual causal treatment effects on the multivariate surrogate and true endpoints, while the second one quantifies the treatment-corrected association between the multivariate surrogate and the true endpoint outcomes. The newly proposed methodology is implemented in the R package Surrogate and a Web Appendix, detailing how the analysis can be conducted in practice, is provided. Supplementary materials for this article are available online.

Funding

The research leading to the results described in this article has received funding from the European Seventh Framework Programme [FP7 2007–2013] under grant agreement number 602552.

History

Usage metrics

    Statistics in Biopharmaceutical Research

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC